Hysteroscopic surgery
Conditions
Interventions
Oliceridine 0.035mg/kg group:The induction dose of oliceridine is 0.035mg/kg
Oliceridine 0.04mg/kg group:The induction dose of oliceridine is 0.04mg/kg
Sufentanil 0.15ug/kg group:The induced dose of sufentanil is 0.15ug/kg group
Oliceridine 0.045mg/kg group:The induction dose of oliceridine is 0.045mg/kg
Oliceridine 0.05mg/kg group:The induction dose of oliceridine is 0.05mg/kg
Oliceridine 0.055mg/kg group:The induction dose of oliceridine is 0.055mg/kg
Sponsors
Women’s Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: ASA LEVELS I-II; Age 18-60 years; BMI 18-24kg/m^2; Patients undergoing elective hysteroscopic surgery requiring intravenous general anesthesia; Patients have no cardiovascular and cerebrovascular diseases, no electrolyte disorders, infection, immunity, endocrine system diseases, and have not taken cardiovascular drugs, non-steroidal anti-inflammatory drugs, hormonal drugs and drugs acting on the central nervous system and other drugs that the investigator believes have a related effect on the drug effect.
Exclusion criteria
Exclusion criteria: Combined with a clear history of psychiatric sleep problems (depression, schizophrenia, sleep disorders); Patients with cognitive dysfunction or communication disorders, central nervous system diseases, abnormal liver and kidney function, abnormal cardiopulmonary function; ECG QT interval > 450ms patients; Long-term opioid users; People who are allergic to opioids; Those who are allergic to ocellidine; sleep apnea syndrome; history of previous spontaneous delivery; Patient refuses to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The concentration of propofol effect chamber (EC50) required to inhibit cervical dilation in 50% of patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Awakening time;The concentration of the propofol effect chamber at each time point (when losing consciousness, after cervical dilation, when stopping the use of propofol, and when regaining consciousness);The concentration of propofol effect chamber (EC50) required to inhibit cervical dilation in 95% of patients;The dosage of propofol per minute;The total dosage of propofol; | — |
Countries
China
Contacts
Public ContactXu Lili
Women’s Hospital, Zhejiang University School of Medicine
Outcome results
None listed